Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Lifted by Leeward Investments LLC MA

Leeward Investments LLC MA lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 20.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,615 shares of the medical equipment provider's stock after acquiring an additional 28,240 shares during the quarter. Leeward Investments LLC MA owned 0.07% of Hologic worth $10,292,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Smithfield Trust Co raised its position in shares of Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares during the last quarter. Raiffeisen Bank International AG acquired a new stake in Hologic in the 4th quarter valued at about $49,000. Finally, West Financial Advisors LLC acquired a new stake in Hologic in the 1st quarter valued at about $50,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.88% of the company's stock.

Hologic Price Performance

HOLX stock traded down $0.41 during trading on Monday, reaching $64.37. 1,789,707 shares of the company were exchanged, compared to its average volume of 2,376,827. The company has a market cap of $14.34 billion, a P/E ratio of 27.16, a PEG ratio of 2.37 and a beta of 0.55. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The stock's 50 day moving average price is $60.71 and its 200 day moving average price is $63.65. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.03 earnings per share. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Evercore ISI decreased their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Royal Bank Of Canada reduced their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Finally, Morgan Stanley cut their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.